“…The point estimates from other studies have suggested reduced (34,39,45,47,54), null (31,42), and increased (35,37,41) risks of colorectal cancer for Ala/Ala versus Glu/ Glu. In a meta-analysis of eight previous studies, Ala/Ala versus Glu/Glu was associated with a nonsignificant 17% reduction in colorectal cancer risk, however, statistically significant heterogeneity between studies was observed (11 (59,60). MTR Asp 919 Gly has been inconsistently associated with colorectal cancer risk (31,37,38,43,55,56), with two studies reporting a statistically significant reduced risk for Gly/Gly versus Asp/Asp (38,55 For this analysis, we pooled men and women from two similar studies, the NHS and HPFS, which are both large prospective cohort studies of female and male health professionals that have used similar methods for participant recruitment, blood collection, diet assessment, and follow-up.…”